HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.

This time, the sTIL densities were highly significant (PFS log-rank p = 0.0009) (Table 2 C).

also in 18,000 other papers

In contrast, % OD-positive cells were left only weakly significant ( p = 0.029), while bSPS showed no significance anymore ( p = 0.13).

also in 211 other papers